AstraZeneca, ABD’de 32 bin 449 ki\u015fi \u00fczerinde devam eden, Kovid-19 a\u015f\u0131s\u0131n\u0131n 3. faz \u00e7al\u0131\u015fmalar\u0131n\u0131n orta g\u00fcvenlik ve aktiflik tahlillerine ait datalar\u0131 payla\u015ft\u0131.<\/p>\n

Ba\u011f\u0131ms\u0131z Data G\u00fcvenli\u011fi \u0130zleme \u015euras\u0131n\u0131n (DSMB) a\u015f\u0131yla ilgili hi\u00e7bir g\u00fcvenlik sorunu tespit etmedi\u011fi bilgisine yer verilen a\u00e7\u0131klamada, Kovid-19 a\u015f\u0131s\u0131n\u0131n 65 ya\u015f \u00fcst\u00fcndekilerde y\u00fczde 80, belirtileri \u00f6nlemede y\u00fczde 79 tesirli oldu\u011fu, hastanede yat\u0131\u015f\u0131 ve a\u011f\u0131r hastal\u0131\u011f\u0131 da y\u00fczde 100 engelledi\u011fi a\u00e7\u0131kland\u0131. Oxford-AstraZeneca’n\u0131n geli\u015ftirdi\u011fi a\u015f\u0131 ge\u00e7en y\u0131l \u0130ngiltere’deki denemelerde y\u00fczde 62 aktiflik g\u00f6stermi\u015fti. ABD’de yap\u0131lan \u00e7al\u0131\u015fmalarda a\u015f\u0131n\u0131n koruyuculuk oran\u0131n\u0131n, \u0130ngiltere’de a\u00e7\u0131klanan datalar\u0131n \u00fcst\u00fcnde oldu\u011fu belirtildi.<\/p>\n

A\u00e7\u0131klamada, DSMB’nin, en az bir doz Kovid-19 a\u015f\u0131s\u0131 olan 21 bin 583 i\u015ftirak\u00e7i ortas\u0131nda yapt\u0131\u011f\u0131 incelemede damarda kan p\u0131ht\u0131la\u015fmas\u0131na ait olaylarda artan bir riske rastlamad\u0131\u011f\u0131na dikkat \u00e7ekildi. A\u00e7\u0131klamada de\u011ferlendirmelerine yer verilen ABD’deki Rochester \u00dcniversitesi T\u0131p Fak\u00fcltesi \u00d6\u011fretim Vazifelisi Ann Falsey, elde edilen son bulgular\u0131n daha \u00f6ncekilerle benzeri aktiflik sonu\u00e7lar\u0131n\u0131 ortaya koydu\u011funu s\u00f6z etti.<\/p>\n

Falsey, 3. faz sonu\u00e7lar\u0131n\u0131n her ya\u015ftan insan\u0131n salg\u0131na kar\u015f\u0131 korunmada bu a\u015f\u0131dan yararlanabilece\u011fine dair bir inan\u00e7 sundu\u011funu, Oxford-AstraZeneca’n\u0131n Kovid-19 a\u015f\u0131s\u0131n\u0131n \u00e7ok muhta\u00e7l\u0131k duyulan bir a\u015f\u0131lama se\u00e7ene\u011fi oldu\u011funu kaydetti.<\/p>\n

BioPharmaceuticals Ar-Ge Lider Yard\u0131mc\u0131s\u0131 Mene Pangalos, sonu\u00e7lar\u0131n, bu a\u015f\u0131n\u0131n Kovid-19’un her \u015fiddetine kar\u015f\u0131 t\u00fcm ya\u015f k\u00fcmelerine iyi geldi\u011fini g\u00f6steren ispatlara katk\u0131da bulundu\u011funu belirtti.<\/p>\n

Bulgular\u0131 ABD Besin ve \u0130la\u00e7 Y\u00f6netimine sunacaklar\u0131n\u0131 s\u00f6yleyen Pangalos, acil kullan\u0131m\u0131na m\u00fcsaade verilmesi durumunda ABD’de milyonlarca a\u015f\u0131y\u0131 piyasaya s\u00fcrmek i\u00e7in haz\u0131rl\u0131k yapt\u0131klar\u0131n\u0131 tabir etti.<\/p>\n<\/p>\n

Bloomberg HT<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

AstraZeneca, ABD’de 32 bin 449 ki\u015fi \u00fczerinde devam eden, Kovid-19 a\u015f\u0131s\u0131n\u0131n 3. faz \u00e7al\u0131\u015fmalar\u0131n\u0131n orta g\u00fcvenlik ve aktiflik tahlillerine ait …<\/p>\n","protected":false},"author":1,"featured_media":28183,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[46,196],"class_list":["post-28182","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ekonomi","tag-abd","tag-asi"],"yoast_head":"\n